Fuji Pharma Co., Ltd. (TYO:4554)

Fuji Pharma Balance Sheet

Financials in millions JPY. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Cash & Equivalents	6,695	4,585	2,324	3,546	10,199	12,041
Cash & Short-Term Investments	6,695	4,585	2,324	3,546	10,199	12,041
Cash Growth	386.91%	97.29%	-34.46%	-65.23%	-15.30%	41.76%
Accounts Receivable	16,877	18,426	16,304	12,527	11,866	11,700
Other Receivables	199	453	216	134	118	8
Receivables	17,076	18,879	16,520	12,661	11,984	11,708
Inventory	22,541	18,005	19,371	15,823	12,006	10,680
Other Current Assets	1,247	999	899	2,697	645	546
Total Current Assets	47,559	42,468	39,114	34,727	34,834	34,975
Property, Plant & Equipment	20,312	20,911	20,547	18,762	14,392	12,767
Long-Term Investments	11,448	13,036	14,702	10,211	11,265	10,131
Goodwill	-	88	412	691	865	1,144
Other Intangible Assets	11,987	12,356	10,081	9,713	1,532	1,755
Long-Term Deferred Tax Assets	1,365	1,139	475	1,432	1,349	1,189
Other Long-Term Assets	1	2	1	2	2	1
Total Assets	92,672	90,000	85,332	75,538	64,239	61,962
Accounts Payable	6,577	4,140	5,672	6,249	5,713	3,680
Accrued Expenses	794	560	883	990	982	438
Short-Term Debt	15,300	15,300	11,300	8,300	7,000	1,000
Current Portion of Long-Term Debt	2,181	7,100	5,210	2,440	1,840	1,640
Current Portion of Leases	573	569	514	377	681	516
Current Income Taxes Payable	338	1,567	484	444	823	460
Other Current Liabilities	4,445	6,561	5,708	5,175	3,153	3,270
Total Current Liabilities	30,208	35,797	29,771	23,975	20,192	11,004
Long-Term Debt	9,901	1,583	8,683	11,193	6,633	7,590
Long-Term Leases	4,415	4,702	3,241	2,259	2,508	1,444
Other Long-Term Liabilities	221	227	598	541	570	416
Total Liabilities	46,939	44,439	44,156	39,734	31,560	22,002
Common Stock	3,885	3,799	3,799	3,799	3,799	3,799
Additional Paid-In Capital	4,492	4,406	4,409	4,409	4,409	5,841
Retained Earnings	34,995	34,256	29,082	26,546	24,628	30,424
Treasury Stock	-498	-505	-567	-579	-590	-68
Comprehensive Income & Other	2,856	3,602	4,451	1,627	432	-38
Total Common Equity	45,730	45,558	41,174	35,802	32,678	39,958
Minority Interest	3	3	2	2	1	2
Shareholders' Equity	45,733	45,561	41,176	35,804	32,679	39,960
Total Liabilities & Equity	92,672	90,000	85,332	75,538	64,239	61,962
Total Debt	32,370	29,254	28,948	24,569	18,662	12,190
Net Cash (Debt)	-25,675	-24,669	-26,624	-21,023	-8,463	-149
Net Cash Per Share	-1054.80	-1014.74	-1095.58	-865.39	-315.00	-4.78
Filing Date Shares Outstanding	24.43	24.31	24.3	24.29	24.29	31.16
Total Common Shares Outstanding	24.43	24.31	24.3	24.29	24.29	31.16
Working Capital	17,351	6,671	9,343	10,752	14,642	23,971
Book Value Per Share	1872.05	1873.87	1694.21	1473.66	1345.50	1282.41
Tangible Book Value	33,743	33,114	30,681	25,398	30,281	37,059
Tangible Book Value Per Share	1381.34	1362.03	1262.45	1045.42	1246.81	1189.37
Order Backlog	-	1,697	1,672	1,313	213	115

Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.